Valuable, Cost-Effective Thyroid Cancer Diagnosis

By João L. Carapinha

January 10, 2025

In this article we highlight the importance of using cost-effective diagnostic methods for thyroid cancer diagnosis, particularly through Galectin-3 based immunohistochemistry. This approach is especially crucial for low- and middle-income countries, where financial constraints can limit access to advanced diagnostic solutions.

Global Pandemic of Thyroid Nodules

Thyroid nodules (TNs) are highly prevalent, affecting approximately one in four people globally, and their management poses a significant financial burden on healthcare systems, especially in low- and middle-income countries (LMICs).

Diagnostic Challenges

The primary challenge is identifying the rare malignant nodules among the multitude of benign ones to avoid unnecessary surgery. Cytologically indeterminate thyroid nodules (Bethesda categories III and IV) are particularly problematic.

Advanced Molecular Tests

Advanced molecular tests, such as Gene Expression Classifier (GEC), BRAF mutation analysis, and mutation/fusion (M/F) panels, are accurate but expensive (costing up to $3,000 to $5,000 per test). These tests are often covered by insurance in high-income countries but are not feasible for many LMICs due to their high cost.

Galectin-3 Immunohistochemistry

Galectin-3 based immunohistochemistry (IHC) is a cost-effective and reliable method for diagnosing thyroid cancer. This test is particularly effective for indeterminate thyroid nodules and has been validated in several multicentric clinical trials. With a cost of approximately $100, it is significantly cheaper than advanced molecular tests.

Diagnostic Performance

Galectin-3 ThyroTest has a sensitivity of 83%, specificity of 85%, and an accuracy of 84%. This is comparable to, though not as high as, some advanced molecular tests. However, its low cost and ease of performance make it a viable option, especially in resource-limited settings.

Cost-Effective Thyroid Cancer Diagnosis

LMICs need cost-effective analyses and priority-setting in thyroid cancer diagnosis. Galectin-3 ThyroTest, a laboratory-developed test (LDT), is not commercially distributed but can be integrated into patient care without the need for extensive regulatory approval. This makes it more accessible and cost-effective compared to commercially marketed advanced molecular tests.

Future Perspectives

Galectin-3 ThyroTest could serve as an initial diagnostic step, with advanced molecular methods used as an adjunctive option for nodules with inconclusive results. This approach could significantly reduce the socioeconomic burden of managing suspicious thyroid nodules, particularly in LMICs.

Conclusion

Galectin-3 based immunohistochemistry is a valuable and cost-effective method for diagnosing thyroid cancer, especially in settings where advanced molecular tests are financially unfeasible. There’s a need to recognize and utilize such “good enough” methods to improve healthcare outcomes and reduce the economic burden associated with thyroid cancer management. The integration of Galectin-3 testing can pave the way for better accessibility to diagnostic resources in low-resource environments.

Reference url

Recent Posts

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.